Category: Bio & Healthcare

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN will participate in the ‘2026 BofA Korea Conference’ sponsored by Bank of America at the Grand Hyatt Hotel to hold 1-on-1 and group meetings with foreign institutional investors regarding its business status and R&D progress. 📊 [Key Disclosure Details & Major Figures Summary] 📝 Editor’s…

Read More “[Disclosure] ALTEOGEN (196170) – Investor Relations (IR) Host / 2026-06-16” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has expanded a contract manufacturing agreement originally disclosed in March 2026, increasing the value from KRW 350.0B to KRW 400.7B upon the client’s request. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Future Amended Disclosures Regarding Changes in…

Read More “[Disclosure] Samsung Biologics (207940) – (Correction) Contract Signings for Supply and Sales / 2026-06-09” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Following Celltrion’s bonus issue, the ex-rights reference price for common stock effective June 4, 2026, has been set at KRW 179,100. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Monitoring Price Adjustments and Respective New Share Listing Dates This disclosure…

Read More “[Disclosure] Celltrion (068270) – Notice of Ex-Rights Reference Price / 2026-06-02” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Following Celltrion’s bonus issue decision, the Korea Exchange (KRX) will adjust the base prices, contract multipliers, and exercise prices for Celltrion stock futures and options effective June 4, 2026. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Derivatives…

Read More “[Disclosure] Celltrion (068270) – Market Measures for Stock Futures and Options Following Bonus Issue / 2026-06-02” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has published its ‘Samsung Biologics ESG Report 2026’ on its official website, detailing its economic, environmental, and social ESG performance and quantitative metrics (ESG Factbook) for FY2025. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Annual…

Read More “[Disclosure] Samsung Biologics (207940) – Matters Related to Sustainability Report / 2026-06-01” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion is modifying its stock listing on June 4, 2026, reducing its total issued common shares to 221,633,364 following the cancellation of 488,977 treasury shares. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Total Issued Shares Reduction and…

Read More “[Disclosure] Celltrion (068270) – Modification of Listing (Stock Cancellation) / 2026-05-29” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has submitted an application for marketing authorization of CT-P6 SC, a subcutaneous formulation of Herzuma, to the Ministry of Food and Drug Safety (MFDS) in South Korea based on successful Phase 1 clinical trial results. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment…

Read More “[Disclosure] Celltrion (068270) – CT-P6 SC (Herzuma Subcutaneous) Korea Marketing Authorization Application / 2026-05-28” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Following Celltrion’s bonus issue decision, the Korea Exchange (KRX) plans to adjust the base prices, contract multipliers, and strike prices for Celltrion stock futures and options starting June 4, 2026, the ex-rights date. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint)…

Read More “[Disclosure] Celltrion (068270) – Planned Stock Futures and Options Market Measures Following Bonus Issue / 2026-05-27” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has decided to acquire approximately KRW 100.0B (557,414 shares) of its own common stock through open market purchases to stabilize share price and enhance shareholder value. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Actual Execution Progress…

Read More “[Disclosure] Celltrion (068270) – Decision on Acquisition of Treasury Shares / 2026-05-21” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has decided to conduct a bonus issue, allocating 0.05 new common shares for every 1 existing share held (total of 10,920,342 new shares). 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Ex-Rights Execution Date and Final New…

Read More “[Disclosure] Celltrion (068270) – Decision on Bonus Issue / 2026-05-21” »